Search

Your search keyword '"Service d'hépatologie"' showing total 2,048 results

Search Constraints

Start Over You searched for: Author "Service d'hépatologie" Remove constraint Author: "Service d'hépatologie"
2,048 results on '"Service d'hépatologie"'

Search Results

2. Non-invasive diagnosis and follow-up of portal hypertension

3. A consensus integrated care pathway for patients with primary biliary cholangitis: a guideline-based approach to clinical care of patients

4. Contribution of Liver Stiffness Measurement by Vibration-Controlled Transient Elastography to Outcome Prediction in Primary Biliary Cholangitis

5. Subclinical proximal tubulopathy in hepatitis B: The roles of nucleot(s)ide analogue treatment and the hepatitis B virus

6. Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort Study

7. Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance

8. Hépatite C en milieu psychiatrique : un réservoir oublié ?

9. Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort)

10. Long term results of liver transplantation for alpha-1 antitrypsin deficiency

11. Novel defatting strategies reduce lipid accumulation in primary human culture models of liver steatosis

12. Sofosbuvir-Daclatasvir Is Suboptimal in Patients with Genotype 2 Chronic Hepatitis C Infection: Real-life Experience from the HEPATHER ANRS CO22 Cohort

13. Simple Magnetic Resonance Scores Associate With Outcomes of Patients With Primary Sclerosing Cholangitis

14. Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication

15. Direct-acting antiviral agent–based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study

16. Baseline and Post-Treatment Hepatitis C NS5A Resistance in Relapsed Patients from a Multicentric Real-Life Cohort

17. [Hepatitis C in a psychiatric setting: A forgotten reservoir?]

18. Insulin receptor isoform A favors tumor progression in human hepatocellular carcinoma by increasing stem/progenitor cell features

19. Efficacy of vedolizumab in perianal Crohn's disease: the BioLAP multi-centre observational study

20. The variation of faecal calprotectin level within the first months after bowel resection is predictive of endoscopic postoperative recurrence in patients with Crohn's disease

21. Effectiveness and safety of ustekinumab 90 mg every 4 weeks in Crohn's disease

22. Non-virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohort

23. Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy

24. Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort

25. Non-contrast MR lymphography of the lymphatic system of the liver NON-CONTRAST MR LYMPHOGRAPHY OF THE LYMPHATIC SYSTEM OF THE LIVER

26. Circulating levels of 3-hydroxymyristate, a direct quantification of endotoxaemia in noninfected cirrhotic patients

27. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial

28. Large‐scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis

29. French Intensive Care Society, International congress – Réanimation 2016

30. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs

31. The epidemiology of Budd–Chiari syndrome in France

32. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study

33. 12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation

34. Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients

35. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis

36. The negative impact of HBV/HCV coinfection on cirrhosis and its consequences

37. High-frequency ultrasound quantification of acute radiation dermatitis: pilot study of patients undergoing radiotherapy for breast cancer

38. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme

39. Screening of antigenic vesicular fluid proteins of Echinococcus multilocularis as potential viability biomarkers to monitor drug response in alveolar echinococcosis patients

40. Prediction of hepatocellular carcinoma recurrence after liver transplantation: Comparison of four explant-based prognostic models

41. Impact of Cytomegalovirus infection on the outcome of patients with cirrhosis: a preliminary study

42. Efficacy and Safety of Sofosbuvir plus Daclatasvir for Treatment of HCV-associated Cryoglobulinemia Vasculitis

43. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial

44. Efficacy and safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation (ANRS HC29 BOCEPRETRANSPLANT)

45. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications

46. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients

47. A new method for the direct quantification of lipopolysaccharide by High Performance Liquid Chromatography coupled with Mass Spectrometry in non-infected cirrhotic patients (The MICROCIR cohort)

48. A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)

49. Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)

50. Long term results of liver transplantation for Wilson’s disease: Experience in France

Catalog

Books, media, physical & digital resources